↓ Skip to main content

Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis

Overview of attention for article published in Gene Therapy, November 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
2 news outlets
twitter
6 X users
patent
19 patents

Readers on

mendeley
84 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis
Published in
Gene Therapy, November 2014
DOI 10.1038/gt.2014.101
Pubmed ID
Authors
Abstract

Nonsense-mediated mRNA decay (NMD) is an RNA surveillance mechanism that requires upframeshift protein 1 (UPF1). This study demonstrates that human UPF1 exerts protective effects in a rat paralysis model based on the amyotrophic lateral sclerosis (ALS)-associated protein, TDP-43 (transactive response DNA-binding protein 43 kDa). An adeno-associated virus vector (AAV9) was used to express TDP-43 throughout the spinal cord of rats, inducing reproducible limb paralysis, to recapitulate the paralysis in ALS. We selected UPF1 for therapeutic testing based on a genetic screen in yeast. The expression of human TDP-43 or human UPF1 in the spinal cord was titrated to less than twofold over the respective endogenous level. AAV9 human mycUPF1 clearly improved overall motor scores in rats also expressing TDP-43. The gene therapy effect of mycUPF1 was specific and reproducible compared with groups receiving either empty vector or green fluorescent protein vector controls. The gene therapy maintained forelimb motor function in rats that would otherwise become quadriplegic. This work helps validate UPF1 as a novel therapeutic for ALS and other TDP-43-related diseases and may implicate UPF1 and NMD involvement in the underlying disease mechanisms.Gene Therapy advance online publication, 6 November 2014; doi:10.1038/gt.2014.101.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Geographical breakdown
Country Count As %
United Kingdom 1 1%
Unknown 83 99%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 21 25%
Student > Ph. D. Student 18 21%
Student > Bachelor 10 12%
Student > Master 8 10%
Other 3 4%
Other 10 12%
Unknown 14 17%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 22 26%
Agricultural and Biological Sciences 17 20%
Medicine and Dentistry 13 15%
Neuroscience 10 12%
Engineering 3 4%
Other 4 5%
Unknown 15 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2025.
All research outputs
#1,360,615
of 24,717,692 outputs
Outputs from Gene Therapy
#65
of 3,051 outputs
Outputs of similar age
#15,701
of 268,371 outputs
Outputs of similar age from Gene Therapy
#3
of 31 outputs
Altmetric has tracked 24,717,692 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,051 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,371 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.